Introduction
Amyotrophic lateral sclerosis (ALS) is a multifactorial disease characterized by the progressive degeneration of motor neurons (MN) and muscle paralysis. Despite current treatments, patients survive less than 3-5 years after the initial diagnosis. Most ALS cases are sporadic (sALS), and only 5-10% have a familial origin (fALS). Among the latter, about 20% express a dominant mutant form of the Cu, Zn superoxide dismutase (SOD1) (Rothstein, 2009) . Transgenic mice expressing a mutant SOD1 develop MN pathology, with muscle 3 denervation and weakness similar to ALS patients (Fischer et al., 2004 ). Many evidence demonstrate that ALS is non-cell autonomous , with multiple co-players involved in disease progression (Robberecht et al, 2013) . In particular, signals from both glial cells and muscles initiate and sustain MN degeneration (Boillée et al., 2006; Dobrowolny et al, 2008) .
Neuroinflammation is often associated with ALS (Philips et al., 2011) : microglial reactivity, astrogliosis and lymphocyte infiltration are common in patients and in experimental models of the disease (Hall et al., 1998; Mantovani et al., 2009; Turner et al., 2004) . Microglia carrying mutant SOD1 express pro-inflammatory genes, such as il-1, tnf-α and inos (Philips et al., 2011; Almer et al., 1999; Henkel et al., 2004) . Nevertheless, the exact contribution of (Feske et al., 2015; Zierler et al., 2016) . In this work, we investigated the role of the intermediate-conductance, Ca 2+ -activated K + channel KCa3.1, in shaping the activation state of microglia in a mouse model of ALS, the hSOD1 G93A mice, which recapitulates many features of the human disease. In the CNS, KCa3.1 channels are expressed by microglial cells, where they regulate cell migration and phagocytic activity in physiological and pathological conditions such as glioma, ischemia, spinal cord injury (SCI) and Alzheimer's disease (AD) (Chen et al., 2011; Maezawa et al., 2012; Bouhy et al., 2011; D'Alessandro et al., 2013; Grimaldi et al., 2916) . In some conditions (SCI), the expression of KCa3.1 is also reported on astrocytes and neurons (Bouhy et al., 2011) . In AD, microglial KCa3.1 potentiate the neurotoxicity induced by oligomeric amyloid-β and lipopolysaccharide (LPS) treatment (Maezawa et al., 2012; Kaushal et al., 2007) ; while blocking KCa3.1 activity has beneficial effects in rodent models of multiple sclerosis and ischemic stroke, reducing TNF-α and IFN-γ expression in the spinal cord (Reich et a., 2005) or the infarcted area (Chen et al., 2016) . The
KCa3.1 inhibitor per se is not directly neuroprotective in the absence of microglia (Maezawa et al., 2011; D'Alessandro et al., 2016 ).
In the current study, we treated hSOD1 G93A mice with the selective KCa3.1 inhibitor TRAM-34 starting at the pre-symptomatic stage and analyzed the activation state of spinal cord microglia by measuring the expression levels of "pro" and "anti-inflammatory" genes and cell morphology. We found that the chronic inhibition of KCa3.1 activity in hSOD1 G93A mice: i) restrained the pro-inflammatory phenotype of microglia; ii) increased the number of healthy MNs; iii) preserved the number of healthy neuromuscular junctions (NMJ) in the tibialis anterior muscle; iv) and their maturation level, as assessed by mRNA analysis of AChR γ and ε subunit expression and by current recording on isolated muscle fibres. Furthermore, TRAM-34 treatment delayed motor symptom appearance, as shown by prolonged muscle strength and motor coordination, and increased mice survival. Taken together, these data demonstrate a crucial role for microglia in modulating disease onset and progression, and provide prove-ofconcept for the potential targeting of KCa3.1 to reduce ALS-associated neuroinflammation and to protect MNs from degeneration.
Materials and Methods

Animal model.
The study was conducted in accordance with the ARRIVE guidelines (Kilkenny et al., 2010 genetic background. Age-matched non-transgenic C57BL/6J mice were always used as control mice. Only male mice were used for the experiments to minimize gender-induced differences in motor impairment and survival (Choi et al. 2008) . Transgenic mice were identified by PCR on DNA obtained from tail biopsies. Briefly, tail tips were digested (overnight, 58 °C) in a buffer containing 100mM Tris-HCl pH 8, 0.1 % SDS 20, 5mM EDTA pH8, 200mM NaCl and 20 mg/ml proteinase K (Ambion-Thermo Fisher, Germany, #2548) and the genomic DNA was amplified with SsoFast Eva Green Supermix (Bio-Rad, California, #172-5201) using the following primers: SOD1 forward 5′-CATCAGCCCTAATCCATCTGA-3′; SOD1 reverse 5′-CGCGACTAACAATCAAAGTGA-3′. Animals were housed in regular polycarbonate cages (30 x 16 x 11 cm), 2-3 per cage, at constant temperature (22 ± 1 °C) and humidity (50%), and were kept on a 12-h light cycle (light 7 a.m.to 7 p.m.). Housing comprised nesting objects, with bedding (sawdust) materials.
Food (regular chow, containing 14% protein, 5% fat, 3041 kcal ME/kg) and water were freely available. Microbiological analyses were routinely (each 3-4 months) performed and defined endemic Norovirus and Helicobacter in our conventional animal facility. Transgenic animals were weighed two times a week, beginning at 7 weeks of age. Starting at 6 weeks of age mice were evaluated for motor deficits with a behavioral score system: 0 = Full extension of hind legs away from the lateral midline when the mouse is suspended by tail; the mouse must hold 6 this position for 2 s, and is suspended 2-3 times; 1 = Collapse or partial collapse of leg extension towards lateral midline (weakness) or trembling of hind legs during tail suspension; 2 = Curling of the toes and dragging of at least one limb during walking; 3 = Rigid paralysis or minimal joint movement; foot not used for forward motion; 4 = Mouse cannot stand up in 20 s from either side, euthanasia.
Mice were always treated in blinded fashion. et al., 2013) . TRAM-34 was synthesized as described (Wulff et al., 2000) .
TRAM-
Animals were treated until the age described in the text or until sacrifice for the survival analysis experiments. Animals were sacrificed when unable to stand up within 20 s after being placed on either side.
Isolation of lumbar microglia cells.
Adult microglia were isolated from the lumbar spinal cord tract of age-matched non-transgenic C57BL/6J wt mice (non-tg wt) and hSOD1 G93A mice as described in (Yip et al., 2009) 
Behavioral tests.
Mice were housed in standard breeding cages at a constant temperature (22 ± 1•C) and relative humidity (50 %), with a 12:12 h light:dark cycle (light on 07.00-19.00 h). Food and water were available ad libitum. Behavioral tests started when mice were 7 weeks old. All animals were handled for at least 5 min/day for 2-3 days before starting the experiments.
Inverted grid test.
Mice were placed in the center of a wire grid (40×60cm, suspended 50 cm above a cushioned table) and then the grid was inverted (maximum time allowed 60 s).
The time spent hanging on to the grid was measured. (Rinaldi et al., 2013) 2.8.2 Hindlimb Extension Reflex. Mice were suspended by the tail, and scored for hindlimb extension reflex deficits. The scores were recorded from 0 to 2 as follows: 2, normal extension reflex in both hind limbs; 1.5, imbalanced extension in the hind limbs; 1.0, extension reflex in only one hindlimb; 0.5, the absence of any hindlimb extension; and 0, total paralysis. (Ludolph et al., 2010) 2.8.3 Hanging wire test. To perform this test, mice were allowed to grab a horizontal wire with their front paws and the time spent hanging measured (maximum time allowed 60 s).
Behavior was scored according to the following scale: 1, hanging onto the bar with both forepaws; 2, in addition to 1, attempted to climb onto the bar; 3, hanging onto the bar with two forepaws and one or both hindpaws; 4, hanging onto the bar with all four paws with tail wrapped around the bar; 5, able to walk on the bar to escape. (Rinaldi et al, 2013) 2.8.4 Rotarod test. Motor coordination, strength and balance were assessed using a rotarod apparatus (Ugo Basile, Gemonio Italy, #47650). Animals were placed onto the cylinder at a constant speed of 15 rpm. The arbitrary cut-off time was 300 s., and the longest latency was recorded.
Grip strength test.
The apparatus consisted of a grip strength meter (Ugo Basile, #47200), complete with a force transducer and a grasping device (grid for measurement of the four limbs). The mouse was held at the base of the tail and allowed to grab the grid with either four limbs. The mouse was then pulled gently backwards until it released its grip. The peak force of each trial was taken as a measure of the grip strength.
2.9 Immunofluorescence. Spinal cord slices were prepared from hSOD1 G93A and non-tg wt mice treated with vehicle or TRAM-34 as described. Spinal cord sections (20 μm) were washed in PBS, blocked (3% goat serum in 0.3% Triton X-100) for 1 h, at RT, and incubated overnight at 4°C with specific antibodies diluted in PBS containing 1% goat serum and 0.1% Images were digitized using a CoolSNAP camera (Photometrics, Tucson USA) coupled to an ECLIPSE Ti-S microscope (Nikon, Tokio Japan) and processed using MetaMorph 7.6.5.0 image analysis software (Molecular Device, San Jose USA). Signal co-localization was analyzed measuring the average fluorescence intensity (pixel) of merged signals.
Motor Neuron survival evaluation.
For MN survival, the whole ventral horns of lumbar spinal cord were photographed at ×20 magnification and digitized using a CoolSNAP camera (Photometrics) coupled to an ECLIPSE Ti-S microscope (Nikon) and processed using MetaMorph 7.6.5.0 image analysis software (Molecular Device). The number of MNs was evaluated counting only SMI32-positive cells with typical morphology triangular shape, single well-defined axon, large body diameter ( 20 m) and intact axons and dendrites. This was done in 12 serial slices for each animal and data normalized with respect to non-tg wildtype mice, where the number of healthy MNs was taken as 100 %.
Skeleton analysis.
Microglia from sections of lumbar ventral horns were analyzed by confocal microscopy using IBA1 signal and skeletonized to assess cell morphology. Twenty μm z-stacks were acquired at 0.5 μm intervals using an FV10i laser scanning microscope (Olympus, Tokyo Japan) at ×60 objective. Cell morphology was measured using a method adapted from Morrison (2013) . Maximum intensity projections for the IBA1 channel of each image were generated, binarized, and skeletonized using the Skeletonize 2D/3D plugin in ImageJ, after which the Analyze Skeleton plugin (http://imagej.net/AnalyzeSkeleton) was applied. The average branch number (process end points per cell) for each image with a voxel size exclusion limit of 150 was applied. The number of single and multiple junction points was additionally calculated to give an indication of branching complexity. The areas of the soma and the scanning domain, defined as the perimeter within which individual cells project their dynamic processes, were measured for each cell. 
Results
3.1 KCa3.1 channels modulate spinal microglia in hSOD1 G93A mice.
In the CNS, KCa3.1 is highly expressed in activated microglia (Kaushal et al., 2007) . To investigate the possible involvement of KCa3.1 channels in modulating the phenotype of microglia in the fully symptomatic phase of ALS, we first analyzed the mRNA level of kcnn4, by quantitative real time PCR (qRT-PCR), in microglia isolated from the lumbar region of the spinal cord of 18 week-old hSOD1 G93A mice. Preliminarily, we confirmed that these cells have increased expression of selected inflammatory genes and reduced expression of antiinflammatory ones (Fig.1A, left) , as previously described in ALS mice (Liao et al., 2012; Apolloni et al., 2016) . We found that hSOD1 G93A microglia express high level of kcnn4 (7.54 fold increase in comparison with age-matched non-tg wt mice), suggesting that KCa3.1 channels could play a role in the pro-inflammatory microenvironment observed in ALS (Fig.1A, right) . To directly evaluate the role of KCa3.1 channel activity in modulating microglia phenotype, hSOD1 G93A mice were treated with TRAM-34 (daily, 120mg/kg) from 7 weeks of age (pre-symptomatic stage) until 18 weeks (fully symptomatic stage) (Fig.1B, top) .
The long term treatment is not toxic and does not induce changes in body weight, haematology, blood chemistry or necropsy of any major organs, either in mice or rats (Toyama et al., 2008; Chen et al., 2011) . After this period, microglial cells were isolated and analyzed as in A. As shown in figure 1B, (Fig.1B, right) . As a control, we also analyzed gene expression in microglia Immunofluorescence analysis of the spinal cord, revealed that KCa3.1 inhibition, in hSOD1 G93A mice (scheme of mice treatment in Fig.1C, top) , significantly decreased Iba1 and GFAP staining in the L3-L5 regions, compared to vehicle-treated mice (Fig.1C, center and bottom), further confirming the induction of a reduced inflammatory environment. Iba1-positive cells in these spinal sections were also analyzed for morphological changes by performing skeleton analysis to quantify single cell shape. The data summarized in figure 1D , To assess the possible beneficial effects of KCa3.1 inhibition on ALS progression, we treated hSOD1 G93A mice daily with TRAM-34 or vehicle (as detailed above) from 7-weeks of age until sacrifice ( Fig.2A ). Mice were evaluated during the treatment period for changes in weight, locomotor activity, muscle strength, motor coordination and survival. As shown in Fig.2B , TRAM-34 treatment significantly increased body weight from week 13 to the end stage. Disease onset was retrospectively determined as the age when these mice reached their maximal body weight: KCa3.1 inhibition delayed disease onset of about 3 weeks in hSOD1 G93A mice (Fig.2C ). In addition, KCa3.1 inhibition increased survival time (Fig.2D) compared to vehicle treated mice and significantly prolonged the mean survival time postparalysis, assessed as the age when mice failed to complete the Rotarod test (Fig.2E ).
We also tested locomotor ability, muscle strength and motor coordination in vehicle and TRAM-34 treated hSOD1 G93A mice. The results of these experiments show that in the hanging wire test, the TRAM-34 treated mice ( Figures 2F and 2G) , for the time investigated, always performed with higher scores and spent more time hanging compared to controls. Of note, the TRAM-34-treated mice never reached the lowest score (1) during the symptomatic stage (13-18 weeks), showing a very good, preserved, locomotor ability. In the inverted grid test (Fig.2H) , the average latency to fall recorded for TRAM-34-treated mice was longer compared to vehicle-treated mice at all the time point analyzed. hSOD1 G93A mice were further tested for motor coordination and balance using a Rotarod apparatus. Mice treated with TRAM-34 performed better on the Rotarod (Fig.2I ) and continued to do so until week-21.
The grip strength data (Fig.2L ) obtained for TRAM-34 treated mice showed that the rate of muscle deterioration was lower compared to vehicle treated mice, suggesting a slower disease progression. In addition, mice treated with TRAM-34 showed a preserved hind-limb extension reflex (Fig.2M ) compared to vehicle treated mice from the beginning of the symptomatic stage. Taken together, these results show that KCa3.1 inhibition significantly delays symptom onset, suggesting that these channels are involved in accelerating disease progression.
Motor neurons are protected by selective KCa3.1 inhibition in hSOD1
G93A mice
In order to investigate if the activity of KCa3.1 channels in microglia could be involved in MN death in ALS, another group of hSOD1 G93A mice were treated with TRAM-34 or vehicle from the pre-symptomatic until the disease onset phase (from 7 weeks to 16 weeks of age, scheme on top of Fig.3A ) when the spinal cords were collected. MNs in the ventral horns of the spinal cord regions L3-L5 were stained with an antibody against the non-phosphorylated neurofilament H (SMI32) (a MN marker) and cells with large cell body (diameter ≥ 20 µm)
were counted. The mean number of MNs in wt animals was taken as control value. As shown in figure 3A, KCa3.1 inhibition, in hSOD1 G93A mice, increased MN survival (TRAM-34 52.00 ± 3.13 %, vehicle 38.26 ± 1.38% vs wt 100 ± 1.09%). 
Selective KCa3.1 inhibition counteracts ROS-induced microglia neurotoxicity
Mitochondrial reactive oxygen species (ROS) play a prominent role in the oxidative stress observed in ALS (Barber et al., 2010) . To investigate whether KCa3.1 activity modulates ROS production in microglia, we used sodium azide (NaN 3 ), an inhibitor of the electron transport chain, to increase ROS levels (Ye et al., 2016) . Microglia (from wt mice) were therefore treated with 5µM NaN 3 for 18 h, in the presence or absence of TRAM-34 (2.5µM) or vehicle, and mitochondrial ROS production was evaluated by loading cells with 10µM 2′,7′-dichlorofluorescin diacetate (DCF). Alternatively, microglia were co-incubated for additional 24 h with primary MN to evaluate neurotoxicity.
The data reported in figure 4A show that NaN 3 treatment induced ROS production in microglia and that KCa3.1 channel inhibition reduced it, as measured by cytofluorimetric analysis (DCF + microglial cells were: NaN 3 : 5.4±0.3%; NaN 3 +TRAM-34: 2.8±0.4%). In accordance, MN death (measured as above) increased when MNs were co-cultured for 48h
with microglia pre-treated with NaN 3 (Fig.4B, 19 .06 ± 0.8% control microglia; 71.6 ± 2.04% NaN 3 microglia). Neurotoxicity was abolished when MNs were co-cultured with microglia pre-treated with NaN 3 /TRAM-34 (22.06 ± 1.98%), suggesting that KCa3.1 function is involved in sustaining ROS production in microglia. As shown in the first two bars of Figure   4B , TRAM-34 exerted a minor neuroprotective action also in control co-cultures.
Selective KCa3.1 inhibition preserves neuromuscular junction (NMJ) functionality
In hSOD1 G93A mice, muscle force and motor coordination start to decline at about 10-11 weeks, with clear evidence of NMJ alterations (Dobrowolny et al., 2011) . The functional data reported above suggest that NMJ is preserved for longer time in animals treated with TRAM-34. Therefore, we performed morphological and functional analysis of NMJ in hSOD1
G93A
mice treated with TRAM-34 or vehicle from 7-to 16-weeks of age (Fig.5A, left) . To evaluate the NMJ morphology/integrity, the tibialis anterior (TA) muscle was isolated, stretched and Several signaling pathways contribute to skeletal muscle atrophy in ALS patients as well as in hSOD1 G93A mice (Krasnianki et al., 2005; Dupuis et al., 2006) . Increased expression of the late myogenic transcription factor myogenin (myf4) and the muscle-specific E3 ubiquitin ligase (atrogin 1) were detected in both mouse (Manzano et al., 2011) and human ALS muscles (Léger et al., 2006) . As shown in figure 5B , the mRNA level of atrogin1 and myogenin were reduced in TRAM-34-vs vehicle-treated hSOD1 G93A mice (respectively 0.27-20 fold and 0.69-fold; vehicle n=3 TRAM-34 n =4 atro gin *p<0.002 vs vehicle, myogenin ***p<0.001 vs vehicle). We also measured the expression level of AchRand subunits in vehicle and TRAM-34 treated mice, an index for NMJ denervation (Martinou et al., 1991) . In hSOD1 G93A muscle, at the paralysis stage, expression of AChRγ was upregulated, in agreement with previous studies (Krasnianski et al., 2005) . Data reported in figure 5C show a decreased (0.59-fold)
AChRand an increased (3.08-fold) AChRexpression in TRAM-34 treated hSOD1 G93A mice (vehicle n=4 TRAM-34 n=6, AChRγ ***p<0.001 vs vehicle, AChR ***p<0.001 vs vehicle).
To assess whether TRAM-34 treatment preserves AChR functionality, patch-clamp recordings were performed in acutely dissociated flexor digitorum brevis (FDB) muscle fibres. The single channel properties of AChRs were investigated under cell-attached conditions at the end-plate region. To improve the mechanical stability of the patches, recordings were performed with pipette solutions free of Ca 2+ and Mg 2+ ions. In all recordings obtained from wt mice (13 fibres/5 animals) only one population of ACh-activated channels was observed (Fig.5D, left) . Unitary channel slope conductance was 78.23 ± 1.71 pS, as expected for AChR in the absence of divalent cations. By contrast, in 7 out of 11 recordings obtained in end-plates from 16-weeks old, vehicle treated SOD1 G93A mice (5 mice) two population of channels, differing in amplitude, were observed (Fig.5D, middle) . Slope conductances were 53.15 ± 1.96 pS (23%) and 82.56 ± 1.28 pS (77%), typical values for -and -containing AChRs, respectively. As expected, based on the data reported above, only one population of ACh-evoked channel openings was detected in 10 out of 12 recordings (6 mice) in TRAM-34 treated hSOD1 G93A mice (Fig. 5D, right) 
Discussion
Increasing evidence supports the hypothesis that in ALS, a neuroinflammatory microenvironment support MN degeneration (Fiala et al., 2010; Puentes et al., 2016; Pasetto et al., 2017; Vallarola et al., 2018) . In this paper we demonstrated that in hSOD1
G93A
, a mouse model of fALS, spinal microglia overexpress the calcium-activated potassium channel, KCa3.1, and that blockade of this channel induces a significant delay in the appearance of all symptoms, preserving motor function and slowing disease progression. In the CNS, KCa3.1 is expressed by microglia and transformed cells (Kaushal et al., 2007; Manzano et al., 2011) and, in a model of spinal cord injury, it has been detected on neurons and astrocytes (Bouhy et al., 2011) . In our experimental conditions, we never measured KCa3.1 activity or expression in spinal MN of wt and hSOD1 G93A mice. KCa3.1 channels expressed on microglial cell play important roles in neurodegenerative diseases and in brain tumors modulating cell phenotype (D'Alessandro et al., 2018; Nguyen et al., 2017) . The expression of the mutant SOD1 G93A gene in microglia has been related to MN degeneration and to ALS progression (Boilléè et al., 2006; Beers et al., 2006) . Here we tested the hypothesis that the activity of KCa3.1 channels is associated to a pro-inflammatory phenotype of microglial cells, that favors MN death and disease progression. This is the first study that investigate the role of KCa3.1 channels in ALS, and we demonstrated that the chronic treatment of hSOD1 G93A mice with the KCa3.1 channel inhibitor TRAM-34 modulates the phenotype of spinal 22 microglia. In both ALS patients and mouse models, the expression of pro-inflammatory genes increases (Lu et al., 2016; Lee et al., 2016) , while anti-inflammatory genes decrease (Liao et al., 2012; Apolloni et al., 2016; Lewis et al., 2014) . In line with our hypothesis, we observed that TRAM-34 treatment reverts this trend, increasing the anti-inflammatory (such as arg1, cd163, socs3, and ym1) and decreasing several pro-inflammatory genes (il1β, tnf-α, il6 and inos) in spinal microglia of hSOD1 G93A mice. Interestingly, KCa3.1 blockade induces some phenotypic changes also in microglia of wt mice, increasing the expression of arg1 and ym1
genes, further confirming the role of this channel in the modulation of microglia phenotype.
Like in other neurodegenerative diseases and similarly to brain tumors, microglia play a dual role in early and late stages of ALS (Ferreira et al., 2015) . The expression of BDNF, insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 (FGF-2), and vascular endothelial growth factor are all downregulated in ALS patients (Shruthi et al., 2017; Ohsawa et al., 2010) . We observed that the expression of the neuroprotective factor bdnf is boosted in hSOD1 G93A microglia by inhibiting KCa3.1 activity.
In line with the gene expression data, spinal microglia of TRAM-34 treated hSOD1 G93A mice at symptomatic stage are less amoeboid, have smaller soma and higher branching complexity.
These morphology data reveal that blockade of KCa3.1 activity restores the patrolling activity of microglia in hSOD1 G93A mice. This is in accordance with the higher expression of the metabotropic receptor P2Y12, known to be involved in microglia process mobility (Appel et al., 2011) .
Microglia-MN communication in hSOD1 G93A mice also benefits from the blockade of KCa3.1 channels. The observed neuroprotective effect is likely due to the combination of a reduced inflammatory phenotype and an increased production of the neurotrophin BDNF. Taken together, these data confirm a key role for KCa3.1 in mediating a pro-inflammatory microglia behavior, as described in other CNS diseases, such as AD, multiple sclerosis, spinal cord injury and ischemia (Maezawa et al., 2011; Moloney et al, 2014; Kaushal et al., 2007; Chen et al., 2016) .
These findings are associated with a reduced NMJ damage, seen as less fragmented and better-preserved structure, together with a decreased muscle denervation, demonstrated by a shift in the expression of the  and AChR subunits in hSOD1 G93A mice treated with TRAM-34. We interpret the enhanced expression of the AChR subunit as a consequence of ongoing denervation/reinnervation cycles in TRAM-34 treated mice. Functional recordings on FDB fibres confirmed the expression data. In addition, KCa3.1 inhibition induced a decrease in the expression markers of atrophy normally detected in ALS muscle (Dobrowolny et al., 2011) , such as myogenin and the E3 ubiquitin ligase atrogin 1.
Degeneration of NMJs together with multiple pathogenic mechanisms such as oxidative stress, aberrant protein aggregation, defective axonal transport, neuroinflammation and mitochondrial dysfunction, all contribute to MN failure in ALS (Philips et al., 2011; Barber et al., 2010; Blokhuis et al., 2013; Barber et al., 2006) . In particular, mitochondrial ROS play a prominent role in the oxidative stress observed in ALS (Barber et al., 2010) . We used low concentrations of sodium azide to block the electron transport chain and to induce effects on microglia neurotoxic properties (see Ye et al., 2016) , and observed that KCa3.1 inhibition prevented the consequent increase in ROS production in microglial cells. Notably, in addition to the plasma membrane, KCa3.1 (and other Ca 2+ activated potassium channels such as KCa1.1) are also expressed in the inner membrane of the mitochondria in transformed cells and cardiomyocytes (De Marchi et al., 2009; Aldakkak et al., 2010) . KCa1.1 activation increases respiration and ROS generation in cardiac cells providing protection against ischemia and reperfusion (IR) injury (Stowe et al., 2006) . We hypothesize that, at least the effect of KCa3.1 inhibition on ROS production, could be partially due to the perturbation of K + homeostasis between the mitochondrial matrix and the inter membrane space.
It has been shown that, in GBM, histamine activates KCa3.1 channels through cell hyperpolarization, which in turn induces Ca 2+ influx (Fioretti et al., 2009 ); clemastine, a histamine receptor (H1R) antagonist, ameliorates ALS pathology modulating inflammatory parameters (Apolloni et al., 2016) . Our results are in accordance with a possible mechanism where histamine, released by peripheral mast cells, activates KCa3.1; blocking H1R would also reduce KCa3.1 activity, thus affecting ALS progression.
Conclusions
In conclusion, our data indicate that the blockade of KCa3.1, when initiated in the presymptomatic stage of the disease, elicits broad protective effects in hSOD1 G93A mice inducing: i) anti-inflammatory phenotype in microglia, that re-acquire a proper scanning domain; ii) reduced MN degeneration; iii) an overall delay of disease onset and motor dysfunction and iv) increased mean survival time. Overall, these data describe, for the first time, a critical role for KCa3.1 activity in modulating ALS onset and progression, at least in the hSOD1 G93A murine model investigated here. It remains to be clarified: i) whether the effect of the blockade of KCa3.1 on hSOD1 G93A mice could be relevant in other familiar forms of ALS, and in sALS; ii) the involvement of other target cells such as immune cells or other parenchymal cells. As a potential future application, it is worth to mention that a molecule structurally related to TRAM-34, Senicapoc®, which advanced into Phase-3 clinical trials, has been proven safe in humans (Ataga et al., 2011) . Our data demonstrate that KCa3.1 is a potential target to counteract neuroinflammation and neuromuscular degeneration, at least in familial ALS. Fiala M., Chattopadhay M., La Cava A., Tse E., Liu G., Lourenco E., Eskin A., Liu P.T., Magpantay L., Tse S., Mahanian M., Weitzman R., Tong J., Nguyen C., Cho T., Koo P., , tnf-, il-1, cd163 and arg1 (left) Kaplan-Meier analysis of mice survival. TRAM-34 increased the survival time of hSOD1 G93A mice (TRAM-34: 165 ± 2 days; vehicle: 148 ± 7 days, data are the mean ± SEM *p<0.008 by Log-rank test, n=9). E: Quantification of the mean survival time post-paralysis. TRAM-34:
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16.6 ± 2.41 days (black bar); vehicle: 7.4 ± 0.97 days (white bar) data are the mean ± SEM, n=9 
